Updated Jul 17, 2026
Lew Jennifer has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $73K.
Jennifer Lew is the Executive Vice President and Chief Financial Officer at Annexon, Inc., a clinical-stage biopharmaceutical company. She has a background in finance and has held various roles in financial management within the biotech industry.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-04 | ANNX | Annexon, Inc. | S — Open-market sale | 5.6K | $5.42 | $30K |
| 2026-02-24 | ANNX | Annexon, Inc. | A — Grant or award | 62.5K | $0.00 | |
| 2026-02-20 | ANNX | Annexon, Inc. | S — Open-market sale | 7.9K | $5.11 | $40K |
| 2025-07-14 | ANNX | Annexon, Inc. | S — Open-market sale | 1.1K | $2.58 | $3K |
Jennifer Lew is the Executive Vice President and Chief Financial Officer at Annexon, Inc., a clinical-stage biopharmaceutical company. She has a background in finance and has held various roles in financial management within the biotech industry.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($73K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Lew Jennifer profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.